Status:
RECRUITING
Universal Genetic Testing for Cancer Risk Reduction
Lead Sponsor:
NYU Langone Health
Conditions:
Genetic Testing
Eligibility:
FEMALE
25-39 years
Phase:
NA
Brief Summary
The purpose of this research study is to see if offering genetic testing for cancer-related genes is feasible and acceptable for patients presenting for gynecology clinic visits, instead of needing to...
Eligibility Criteria
Inclusion
- Female patients between ages of 25-39 years at the time of visit
- Receive gynecologic care at an affiliated NYU Langone Health (NYULH) site listed in this protocol.
Exclusion
- Personal history of ovarian, fallopian tube, primary peritoneal, or uterine cancers
- Previously undergone germline testing for ovarian cancer risk variants (prior commercial saliva-based kits, such as 23andMe, are acceptable)
- History of bilateral salpingo-oophorectomy
- Visit related to pregnancy or immediately postpartum (within 2 weeks)
Key Trial Info
Start Date :
March 4 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2027
Estimated Enrollment :
600 Patients enrolled
Trial Details
Trial ID
NCT06926816
Start Date
March 4 2025
End Date
December 31 2027
Last Update
April 15 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
NYU Langone Health
New York, New York, United States, 10016